首页 > 最新文献

Journal of Clinical Psychopharmacology最新文献

英文 中文
Myocarditis on Clozapine 50 mg/d in a Patient With Parkinson's Disease. 帕金森病患者服用氯氮平 50 毫克/天后出现心肌炎。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-25 DOI: 10.1097/JCP.0000000000001927
Luisa Skoble, Stephen Kutz, Joseph H Friedman
{"title":"Myocarditis on Clozapine 50 mg/d in a Patient With Parkinson's Disease.","authors":"Luisa Skoble, Stephen Kutz, Joseph H Friedman","doi":"10.1097/JCP.0000000000001927","DOIUrl":"https://doi.org/10.1097/JCP.0000000000001927","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychopharmacologic Laziness. 精神药理学上的懒惰
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-24 DOI: 10.1097/JCP.0000000000001924
Anthony J Rothschild
{"title":"Psychopharmacologic Laziness.","authors":"Anthony J Rothschild","doi":"10.1097/JCP.0000000000001924","DOIUrl":"https://doi.org/10.1097/JCP.0000000000001924","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aripiprazole-Associated QT Prolongation in a Healthy Study Volunteer: A Case Report and Literature Review. 一名健康研究志愿者的阿立哌唑相关 QT 延长:病例报告与文献综述
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-24 DOI: 10.1097/JCP.0000000000001921
George E Chapman, Martin Osugo, Antonio de Marvao, Oliver D Howes
{"title":"Aripiprazole-Associated QT Prolongation in a Healthy Study Volunteer: A Case Report and Literature Review.","authors":"George E Chapman, Martin Osugo, Antonio de Marvao, Oliver D Howes","doi":"10.1097/JCP.0000000000001921","DOIUrl":"https://doi.org/10.1097/JCP.0000000000001921","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ketamine. The Story of Modern Psychiatry's Most Fascinating Molecule. 氯胺酮。现代精神病学最神奇分子的故事。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-24 DOI: 10.1097/JCP.0000000000001925
Richard Balon
{"title":"Ketamine. The Story of Modern Psychiatry's Most Fascinating Molecule.","authors":"Richard Balon","doi":"10.1097/JCP.0000000000001925","DOIUrl":"https://doi.org/10.1097/JCP.0000000000001925","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bipolar Disorder in a Young Adult With Thalassemia Major With Sequential Development of Neuroleptic Malignant Syndrome and Serotonin Syndrome. 一名患有重型地中海贫血症的青壮年躁郁症患者相继出现神经性恶性综合征和血清素综合征。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-24 DOI: 10.1097/JCP.0000000000001912
K Ragul Kalaimathi, Manish Roshan Thakur, Bhavuk Garg
{"title":"Bipolar Disorder in a Young Adult With Thalassemia Major With Sequential Development of Neuroleptic Malignant Syndrome and Serotonin Syndrome.","authors":"K Ragul Kalaimathi, Manish Roshan Thakur, Bhavuk Garg","doi":"10.1097/JCP.0000000000001912","DOIUrl":"https://doi.org/10.1097/JCP.0000000000001912","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Question: Do You Have Suggestions for Managing a Patient With Bipolar II Disorder, Binge Eating Disorder, and Obesity Who Stops Medications Fearing Weight Gain? 问:患有双相情感障碍 II、暴食症和肥胖症的患者因担心体重增加而停止服药,您对如何管理这类患者有什么建议?
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-24 DOI: 10.1097/JCP.0000000000001929
Susan L McElroy
{"title":"Question: Do You Have Suggestions for Managing a Patient With Bipolar II Disorder, Binge Eating Disorder, and Obesity Who Stops Medications Fearing Weight Gain?","authors":"Susan L McElroy","doi":"10.1097/JCP.0000000000001929","DOIUrl":"https://doi.org/10.1097/JCP.0000000000001929","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antipsychotic Polypharmacy in Time Course: Evidence for a Cross-titration Trap. 抗精神病药物的时间过程:交叉滴定陷阱的证据。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-19 DOI: 10.1097/JCP.0000000000001916
Marc W H Lochmann van Bennekom, Harm J Gijsman, Joanna IntHout, Robbert Jan Verkes

Purpose/background: Antipsychotic polypharmacy (APP) is controversial yet applied in 20% of patients with psychotic disorders. We investigated indications for initiating and continuing APP, including the contribution of unfinished cross-titrations.

Methods/procedures: This 2-month study was part of a prospective study to reduce inappropriate APP in inpatients. With each new prescription resulting in APP, we asked the prescriber for the indication (eg, switching antipsychotics, sedation for agitation/sleep disorders, treatment refractoriness, other) and repeated this at 30 and 60 days. Secondary outcome was unfinished cross-titration at 60 days.

Findings/results: In a consecutive cohort of 55 patients, 80% diagnosed with schizophrenia, switching antipsychotics was the primary initial indication for APP in 31 of 55 patients (56%), followed by sedation in 12 of 55 patients (22%), and treatment refractoriness in 10 of 55 patients (18%). Overall, APP was discontinued after 30 days in 25 of 55 patients (45%) and after 60 days in 28 of 55 patients (51%). At 60 days, APP initiated for switching antipsychotics was ongoing in 9 of 31 patients (29%), APP initiated for sedation was ongoing in 8 of 12 patients (66%), and APP initiated for refractoriness was ongoing in 9 of 10 patients (90%). The initial indication for APP was maintained at 60 days in 21 of 27 patients (78%). Unfinished cross-titration occurred in 9 of 31 patients (29%) with APP initiated for switching antipsychotics.

Implications/conclusions: APP was initiated primarily because of cross-titration switching of antipsychotics. The reason for APP was generally maintained consistently over time, particularly when initiated for treatment refractoriness. Of all patients with APP initiated to switch antipsychotics, 29% ended in unfinished cross-titration.

目的/背景:抗精神病药物多药治疗(APP)备受争议,但仍有 20% 的精神病患者使用这种治疗方法。我们对启动和继续使用 APP 的适应症进行了调查,包括未完成交叉滴定的贡献:这项为期 2 个月的研究是一项前瞻性研究的一部分,旨在减少住院患者不适当使用 APP 的情况。对于每个导致APP的新处方,我们都会询问处方开具者的适应症(如更换抗精神病药物、镇静治疗躁动/睡眠障碍、治疗难治性、其他),并在30天和60天后重复这一过程。次要结果是60天时未完成交叉治疗:在55名患者(80%确诊为精神分裂症)的连续队列中,55名患者中有31名患者(56%)最初使用APP的主要原因是更换抗精神病药物,其次是镇静,55名患者中有12名患者(22%)使用了APP,55名患者中有10名患者(18%)使用了APP。总体而言,55 名患者中有 25 人(45%)在 30 天后停用了 APP,55 名患者中有 28 人(51%)在 60 天后停用了 APP。60天后,31名患者中有9名(29%)因更换抗精神病药物而继续使用APP,12名患者中有8名(66%)因镇静而继续使用APP,10名患者中有9名(90%)因难治性而继续使用APP。27 名患者中有 21 名(78%)在 60 天后仍保留了最初的 APP 适应症。在31例因更换抗精神病药物而使用APP的患者中,有9例(29%)未完成交叉治疗:启动APP的主要原因是交叉滴定转换抗精神病药物。使用APP的原因通常会随着时间的推移而保持一致,尤其是在因治疗难治而启动APP的情况下。在所有因更换抗精神病药物而使用APP的患者中,29%的患者最终未完成交叉治疗。
{"title":"Antipsychotic Polypharmacy in Time Course: Evidence for a Cross-titration Trap.","authors":"Marc W H Lochmann van Bennekom, Harm J Gijsman, Joanna IntHout, Robbert Jan Verkes","doi":"10.1097/JCP.0000000000001916","DOIUrl":"https://doi.org/10.1097/JCP.0000000000001916","url":null,"abstract":"<p><strong>Purpose/background: </strong>Antipsychotic polypharmacy (APP) is controversial yet applied in 20% of patients with psychotic disorders. We investigated indications for initiating and continuing APP, including the contribution of unfinished cross-titrations.</p><p><strong>Methods/procedures: </strong>This 2-month study was part of a prospective study to reduce inappropriate APP in inpatients. With each new prescription resulting in APP, we asked the prescriber for the indication (eg, switching antipsychotics, sedation for agitation/sleep disorders, treatment refractoriness, other) and repeated this at 30 and 60 days. Secondary outcome was unfinished cross-titration at 60 days.</p><p><strong>Findings/results: </strong>In a consecutive cohort of 55 patients, 80% diagnosed with schizophrenia, switching antipsychotics was the primary initial indication for APP in 31 of 55 patients (56%), followed by sedation in 12 of 55 patients (22%), and treatment refractoriness in 10 of 55 patients (18%). Overall, APP was discontinued after 30 days in 25 of 55 patients (45%) and after 60 days in 28 of 55 patients (51%). At 60 days, APP initiated for switching antipsychotics was ongoing in 9 of 31 patients (29%), APP initiated for sedation was ongoing in 8 of 12 patients (66%), and APP initiated for refractoriness was ongoing in 9 of 10 patients (90%). The initial indication for APP was maintained at 60 days in 21 of 27 patients (78%). Unfinished cross-titration occurred in 9 of 31 patients (29%) with APP initiated for switching antipsychotics.</p><p><strong>Implications/conclusions: </strong>APP was initiated primarily because of cross-titration switching of antipsychotics. The reason for APP was generally maintained consistently over time, particularly when initiated for treatment refractoriness. Of all patients with APP initiated to switch antipsychotics, 29% ended in unfinished cross-titration.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health Alert: Microdose Products Leading to Acute Illness and Hospitalizations Across the United States. 健康警报:微剂量产品在全美导致急性疾病和住院治疗。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-17 DOI: 10.1097/JCP.0000000000001919
Elisa Nguyen, Abraham Qavi, Minh-Ha Tran
{"title":"Health Alert: Microdose Products Leading to Acute Illness and Hospitalizations Across the United States.","authors":"Elisa Nguyen, Abraham Qavi, Minh-Ha Tran","doi":"10.1097/JCP.0000000000001919","DOIUrl":"https://doi.org/10.1097/JCP.0000000000001919","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms of Drug-Associated Burning Mouth Syndrome. 药物相关灼口综合征的机理。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-11 DOI: 10.1097/jcp.0000000000001915
Takahiko Nagamine
{"title":"Mechanisms of Drug-Associated Burning Mouth Syndrome.","authors":"Takahiko Nagamine","doi":"10.1097/jcp.0000000000001915","DOIUrl":"https://doi.org/10.1097/jcp.0000000000001915","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142192195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Case Series: Psychotic Disorder Associated With Gummies Containing Delta-8-Tetrahydrocannabinol. 病例系列:与含有δ-8-四氢大麻酚的软糖有关的精神紊乱。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1097/JCP.0000000000001884
David R Spiegel, Jason Bard, Megan Ralston, William Crafton, Alim Osman, Kallen Hager, Pavan Suryadevara
{"title":"A Case Series: Psychotic Disorder Associated With Gummies Containing Delta-8-Tetrahydrocannabinol.","authors":"David R Spiegel, Jason Bard, Megan Ralston, William Crafton, Alim Osman, Kallen Hager, Pavan Suryadevara","doi":"10.1097/JCP.0000000000001884","DOIUrl":"10.1097/JCP.0000000000001884","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical Psychopharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1